Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Cancer Institute (NCI)
USWM, LLC (dba US WorldMeds)
Pfizer
Pfizer
Dragonfly Therapeutics
ViroMissile, Inc.
Tizona Therapeutics, Inc
Adaptimmune
Novartis
TScan Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Actym Therapeutics, Inc.
Memgen, Inc.
MacroGenics
Providence Health & Services
Genentech, Inc.
University of California, San Diego
DEKA Biosciences
Columbia University
Thomas Jefferson University
Revolution Medicines, Inc.
Checkpoint Therapeutics, Inc.
Inhibrx Biosciences, Inc
Xencor, Inc.
Pfizer
Celldex Therapeutics
Adaptimmune
Apexigen America, Inc.
Seagen Inc.
Fate Therapeutics
Rakuten Medical, Inc.
Prelude Therapeutics
Quadriga Biosciences, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
Revolution Medicines, Inc.
Imperial College London
Pfizer
AbbVie
Incyte Corporation
MacroGenics
Fate Therapeutics
Mie University
Tocagen Inc.
University of Wisconsin, Madison
IGF Oncology, LLC
University of Illinois at Chicago
Takara Bio Inc.
PCI Biotech AS